Amgen Inc v. Sanofi
2023 United States Supreme Court case / From Wikipedia, the free encyclopedia
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lower drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).[1]
Quick Facts Amgen, Inc. v. Sanofi, Argued March 27, 2023 Decided May 18, 2023 ...
Amgen, Inc. v. Sanofi | |
---|---|
Argued March 27, 2023 Decided May 18, 2023 | |
Full case name | Amgen, Inc., et al. v. Sanofi, et al |
Docket no. | 21-757 |
Citations | 598 U.S. 594 (more) |
Argument | Oral argument |
Opinion announcement | Opinion announcement |
Holding | |
Petitioner Amgen’s two patent applications—purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism—fail to satisfy the Patent Act’s enablement clause. | |
Court membership | |
| |
Case opinion | |
Majority | Gorsuch, joined by unanimous |
Laws applied | |
Patent Act of 1952 |
Close